SCHEMBL3437209

SCHEMBL3437209

Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OF)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.79
NT5E P21589 1/20 0.74
KRAS P01116 6/20 0.74
FUT5 Q11128 1/20 0.73
P2RX3 P56373 2/20 0.69
P2RY2 P41231 3/20 0.67
P2RY4 P51582 1/20 0.67
P2RY6 Q15077 1/20 0.67
DCPS Q96C86 1/20 0.63
IMPDH2 P12268 1/20 0.63
P2RY1 P47900 3/20 0.62
SRC P12931 1/20 0.62
P2RX1 P51575 1/20 0.62
P2RX4 Q99571 1/20 0.62
P2RX2 Q9UBL9 1/20 0.62
ALDH1A1 P00352 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL407395 0.96 NT5E (0.77) TGM2NT5EKRASFUT5P2RX3
SCHEMBL21067722 0.96 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL29429843 0.96 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL851357 0.96 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL18769114 0.96 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL3437211 0.93 TGM2 (0.79) TGM2NT5EKRASFUT5P2RX3
SCHEMBL32661169 0.93 TGM2 (0.79) TGM2NT5EKRASFUT5P2RX3
SCHEMBL1304258 0.93 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL376140 0.93 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL5809658 0.93 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807653-B2 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2010-10-05 US disclosed
US-7598230-B2 For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2009-10-06 US disclosed
US-20070265224-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-11-15 US disclosed
US-20070259832-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-11-08 US disclosed
US-7285658-B2 Nucleotide mimics and their prodrugs BIOTA, INC. (US) 2007-10-23 US disclosed
EP-1485395-A2 NUCLEOTIDE MIMICS AND THEIR PRODRUGS Biota, Inc. (US) 2004-12-15 EP disclosed
WO-2003072757-A9 NUCLEOTIDE MIMICS AND THEIR PRODRUGS BIOTA INC (US) 2004-10-21 WO disclosed
US-20040059104-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2004-03-25 US disclosed
WO-2003072757-A2 NUCLEOTIDE MIMICS AND THEIR PRODRUGS BIOTA, INC. (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259832-A1 Nucleotide mimics and their prodrugs NUDT14, ENTPD5, MTAP TGM2 4048/4885NT5E 39/4885KRAS 365/4885
US-20070265224-A1 Nucleotide mimics and their prodrugs NUDT14, ENTPD5, MTAP TGM2 4048/4885NT5E 39/4885KRAS 365/4885
US-20040059104-A1 Nucleotide mimics and their prodrugs NUDT14, ENTPD5, MTAP TGM2 4048/4885NT5E 39/4885KRAS 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.